Beacon Topco, Inc. Amends Merger Agreement; Reports Phase 1b Results

What Happened

• Beacon Topco, Inc. (CLYD) filed an 8-K reporting a Second Amendment to the Agreement and Plan of Merger among Topco, its subsidiaries (Beacon and Merger Sub) and Clywedog Therapeutics, dated September 22, 2026. The amendment resets the merger closing timeline so the closing (and the defined “End Date”) will occur on October 31, 2026 (or earlier if the parties agree). Separately, on September 24, 2026 Topco and Clywedog issued a joint press release announcing final Phase 1b results for balomenib in Type 2 diabetes showing glycemic improvement sustained for three months after a three‑week course of treatment.

Key Details

• Second Merger Agreement Amendment executed: September 22, 2026.
• New merger closing / End Date: October 31, 2026 (earlier only if mutually agreed).
• Scheme Transaction note: Topco previously acquired Beacon pursuant to a court‑approved scheme effective September 9, 2026.
• Clinical update: Press release dated September 24, 2026 reports Phase 1b balomenib data — three-week dosing with glycemic improvement sustained for three months.

Why It Matters

• The amendment provides a firm, near‑term timeline (Oct 31, 2026) for completing the contemplated combination with Clywedog, which affects when the combined companies’ operations and strategy will formally align.
• The Phase 1b results are a clinical data disclosure that investors will watch for potential impact on Clywedog’s development prospects and value; the company also included the customary forward‑looking statement cautions.
• Investors should note the filing is procedural (an amendment setting timing) plus a clinical update — both may influence milestone timing, regulatory planning, and investor expectations but do not by themselves change the stated terms of the merger.